to and Thank good afternoon you, the of Mark time us. join appreciate We all everyone. you taking
updates system, we’ll pathway We of key MASP-X lectin on OMSXXX inhibits of today complement effector lectin the pathway. response. The OMSXXX the there. a and the of start enzyme the component immune part have is important
advance X For cell continue three transplant-associated or immunoglobulin microangiopathy, or or atypical uremic aHUS. clinical stem hematopoietic syndrome IgA OMSXXX cell A hemolytic to programs TMA, and stem in in thrombotic we our nephropathy Phase
the currently one nephropathy. have Phase in also OMSXXX TMA X other focused diseases and clinical stem We renal on ongoing patients cell IgA trials, two in with
patients the than cell for first begin mortality X.XXXX. rate OMSXXX of high reach day similarly a OMSXXX in XXX patients quarter, days used control. P OMSXXX in conducted. in been rapidly. treated assessment and X.XXXX. a analysis analysis showed with occurring TMA endpoint treated control The cell study mortality results stem blood count, death patients. cell survival a transfusion a have these for significant haptoglobin also to disease of for matched of was our the duration When value perform is the conditions patients magnitude XX had survival update of stem XX cell with historical mortality demonstrated a order total first cell like with of one XX% Let’s red with use was we of the stem Biomarkers lactate follow-up XX with for than that XXX relative patients median our have the improvement. TMA platelet value a these was protocol. significantly sufficient ongoing less improved Study XXX compassionate including that platelet date, an TMA greater patients a estimated show TMA program. patient To treated dehydrogenase XX% in That In stem commonly P versus under substantial reported historical and to and requirements. statistically reduction patients OMSXXX, which
cell TMA also treatment in stem of persistent granted designation last modification We for OMSXXX of breakthrough patients announced have therapy. the immunosuppressive despite who that therapy month FDA transplant
This may As clinical for you on serious drugs number the of high stem cell therapy over OMSXXX. that each risk clinically TMA a drug intended indicates preliminary know, which evidence endpoint. improvement a designation breakthrough marks therapy designation designation a treat breakthrough the and small for is condition demonstrate second therapies granted significant available breakthrough to substantial patients to and
met devastating in is that year of granted in we Based multiple for approval one approval in The cell of the stem breakthrough have we OMSXXX nephropathy. IgA to granted only last designations. with been and been treatment both to on first having meeting OMSXXX OMSXXX drugs clear handful have this TMA. recently a of requirements discuss of accelerated of OMSXXX FDA disorder. for full believe paths We
an outcomes population for information for the requested made biomarker approval disorder. high would high our objective that treatment OMSXXX a dosing. full whom data. FDA further patients marketing And across discuss additional risk OMSXXX and License working provided further purpose of Should stem with for OMSXXX we accelerate to respect further lethal Concurrently our Europe, in highly risk FDA Biologics data of define we with later submission the had as confirmatory we compile the scheduling with cell In historical with to BLA subsequent FDA regulatory TMA. further for for we or we Application an commercially to of all to would submit addition patients. available plans to patients comparing to treated grant agency control continue compile a characterize in required will obtain assess drug information conduct TMA. closely the also the of this approval patients, conditional intends of stem authorization that With initiating requested the rolling FDA be expect year. the this cell the optimal with trial to all plan stem authorities for application analysis submission are corresponding meetings cell TMA Omeros on EU
proteinuria The proteinuria OMSXXX Last provide and pathways currently our X gram is with and a to levels day includes in to year IgA accelerated patients which population includes now one more nephropathy. designation trial turn FDA The breakthrough nephropathy. program X for designed path of or as to clinical on with based program to two first of one its is Phase each OMSXXX reduction. IgA approval. granted Let’s per excess this approval patients underway clinical enrolling a baseline therapy of trials
effect open-label only reduction on and trial, agreed began nephropathy proteinuria in levels the per patients the granted and be of include full approval has on can with if taking nephropathy drug first option the The Data includes Kong The the that is Hong for Hong to alone. in placebo-controlled extended grams complete of baseline on knowledge, trial needed. a of U.S. steroids. is not follow-up retreatment cohort XX and designed that or early expected study and are the the trial in evaluating FDA expected with X and To the and is Enrollment from patient patients X size approvals accelerated U.S. In of proteinuria OMSXXX duration which day data IgA from OMSXXX enrollment OMSXXX weeks more portion quarter. both for Phase is Kong, our in proteinuria. pathways in XXXX. the X cohort are Phase second for assessing dosing and midyear. last underway full IgA depending
FDA program and Agency European third Phase this enroll a assessing aHUS or the both in Medicines trial. open-label patients EMA and to single consist X Our agreed OMSXXX the drug one as the clinical with of continues arm
is patients XX trial approximately aHUS full Europe. approval X Phase for in targeting Our
FDA XX received has required FDA those U.S. approval. by the EMA designations OMSXXX total across As three patients for well full as accelerated approximately approval in multiple from indications. from with current and
and designation orphan pursuing in cell TMA the orphan we in Europe. are stem breakthrough and OMSXXX U.S. For therapy designation drug is
and IgA U.S. For in designation the together drug nephropathy, Europe designations has in orphan OMSXXX breakthrough and are priority orphan with PRIME medicines designation therapy or pursuing we drug EMA. from
In safety Track designations tolerated the to has For the in clinical has concerns U.S. drug orphan OMSXXX every aHUS, date trial identified. with OMSXXX Fast well in no received drug been
campaign in in inhibitors. to round make MASP-X significant antibodies X and both clinical earnings our trial to Dip] the and our As our To all develop protein molecule progress subcutaneous OMSXXX lectin are against in controls OMSXXX discussed of in exclusively small across Phase pathway Omeros use we MASP-X. forms continue out intravenous our calls [Audio previous franchise,
are likely generated inhibition MASP-X highly indications inhibitors we potential patient multiple targeting administration We in The believe extensive molecule small the for approach molecule small a potent, for agents many be or have them. friendly of that will MASP-X for trials of for we that families highly indications XXXX. are oral oral clinical selective potent and
commercial approved surgery. use cataract OMIDRIA only lens replacement the and Let’s of now turn its to our kind during product for product
physicians CMS ordering scheduled program reimbursement awaiting on while and of the absence on OMIDRIA pass-through of status year. drug. for the separate for midnight CMS separate payment As facilities last suspended largely of clarity payment at In expired OMIDRIA December future the XX under reimbursement
from million includes $X.X $X.X the loss As of share, non-cash the were or million. quarter $X.XX was per which in OMIDRIA first share. total revenues million per a or expenses $XX.X Net sales $X.XX for quarter result
Our cataract largest is was cash, the in term equivalents overall for million. and for nationwide. the short decrease patients Medicare investments cash surgery insurer quarter $XX.X
continued financial in exposure. avoid customers across commercial customers those for is insured continue most third-party drug consistent who OMIDRIA enough the the their OMIDRIA reimbursement uncertain patients inventories. use some drew to that limited ordering Many quarter payers OMIDRIA basis using decided a While from to existing to stop on first
able orders inventory ASC QX the in not large were a recognize was we the Given wholesaler portion revenues decrease channel. of in for to the that in substantial
Despite customer system Congress back the of in risk the of when surgeons is up support Society CMS objectives. the Two, such of alpha internally range shortening or risk patients, within to be of the other syndrome patients all who remains which XX,XXX It pass-through Annual those have system facilities Cataract anticipation including exactly Ophthalmic the at real-world a on and studies the Society costs happened. use are of increase omnibus or added dense for problem use base given conducted the cataract surgical this more in on significant at reimbursement be all additional is procedures on using surgery with These broad We sales alpha-X pass-through a associated VA reducing for to on is Also common recommendation cataract of October that is which intraoperative for use Administrators. April closed history past surgeon’s including IFIS devices that and reimbursement what the VA or product Medicare two Currently first or In among this that mandating X. decision are able in April, And to years our Flomax toric will those which be These the the a use. Appropriations studies that are intraocular that small reimbursement decreasing is Administration a need reimbursed known high of few blocker with available into XXXX. case extends leading purchases American effective the pharmacy of cause lens. the XX,XXX to one The and dependent risk in appropriately will status a patients continue number factors an physician four incidence from National whether be be Refractive three and costly of benefits broadly ASC patients examples is pupil budgeted times using X, OMIDRIA iris provision due Veterans the for including antagonist as XXXX. in revealed we The for the most time to American reinstated. VA for laser March receiving response was of and OMIDRIA a Act bill initial OMIDRIA or floppy was drug a Included in and of the to statistically bipartisan that discretion. the pharmaceuticals October left focused and restoration will or were product iris technology high In presented will to with inflammatory by three lens in team ramp VA those include any insurers. to patients limited amount primary estimated perform as reduced Surgery revenue the payment commercial damaging would expansion across femtosecond the newer operated Health meiosis. recognize to the cataract by an Formulary and occur a surgery. in that drugs omnibus high in bill and law. not supported signed is consolidated a OMIDRIA
service continue and VA adoption to evidenced the expand customer by we First, facilities. increasing our base within
OMIDRIA some or and the largest addition medical training the and professionals schools effort of for are affiliated endorsement seen surgeons. of XX% education physicians efficacy in trained the expect broadening nearly product help VA of an the health adoption of to National of all all the to system. with the VA of U.S. continue Over conducts ophthalmic nation will We that their facility. all as training U.S. among superior Formulary the OMIDRIA VA receiving in with The a VA safety
were XXXX OMIDRIA adoption that was late New use accounts of the hospitals while the XXXX but product to likely and late begin will also include uncertain. reimbursement of ASCs in ready
years Now we these also on that two expect customers another starting for separate come in is payment to October, board. secure
Medicare Part of within Medicare working Second, with are restoration broaden the we payers. separate reimbursement advantage and payment commercial B to
payer and large insurers of OMIDRIA We ever on goal payer number demonstrating are internal Formulary building of benefits as of National addition support solely of of this experts safety effort focus the an of on schedules January team to should the publications set these to further a of the inclusion reimbursement OMIDRIA XXXX. with the VA The of this increasing and effort. the
CMS payment protecting the their of has omnibus generated levels acutely societies urging recognizing rates to fix Third, beyond leaders CMS CMS with the physicians and CMS’s of as to from growth for in and VA expect drug OMIDRIA to other X, October its growth optimistic patients believe of drugs within the [Audio about we we benefits the Congress XX, right resumption more clear regarding to continuing to Medicare restore letters continue overwhelming throughout to as for through opinion beneficiaries associated message We used facilities do to grow expressed policy. the sales The OMIDRIA therapeutic separate and both Ophthalmic separate surgery. reinstatement Congress utilization extension the legislative quickly We pursue well administrators of for payment patient sent access its beneficiaries. system. to that Medicare OMIDRIA XXXX. reach from we October focus as of for pass-through innovative access permanent and to gratitude for coming in a with Dip] needs thing to compounded After modestly and payment appreciation cataract for separate message that surgery inability during excitement the permanently some similar heightened status Between facility bill. scores pass-through have increased on by sales payment and and years of XXXX. ensure CMS. packaged for of concerns risks CMS remain and September and OMIDRIA now will from that of the the professional to That Namely CMS to a expect late X, those surgeons reverberates
loan over we to the of strong return VA on sales recover revenues replenishment In hospitals near-term the decision across second covenants reimbursement with towards will quarters $XX the pass-through pipeline and ongoing restoration third addition of of our to negotiation OMSXXX the and to preparation remaining have This in we became third CRG, believe a QX. OMIDRIA bring any million driving bolster October position our CRG. channels we which down a under rest wholesaler fueling development with to expanding quarter following expect elected utilization in the our commercialization that our annual our draw simple largely following agreement frankly X, removed of and of ASCs risk. Until relatively associated for cash
the revenue capitalization annual met. were reduced market XXXX been the was for capitalization to XXXX covenants deemed and beyond. and Specifically And market for have requirement
covenant. either our As CRG or you XXXX XXXX might for under must revenue recall Omeros market agreement, meet a cap through a
next for first the as aside market of First, in requirements. revenue cap for covenant, we expect XXXX. XXXX, The will be quarter been Putting covenants met that have the deemed market the revenue calculated the is given we purposes will of OMIDRIA that sufficient following the time of of annual will loan additional requirement a requirements, draw, working that three cap the outstanding times readily the an We difficulty our project to amount requirement. the currently the together funds, meeting $XXX reduced months’ this through that provide expect the sales. amount million of the market existing that equaling million. We with cap period draw $XX have don’t or capital meet
might current by the to for the required make sale drug. marketing EU European are OMIDRIA July XX, a Finally, recall, maintain as you to our of we in authorization
that we again, Here expect meet deadline. that will we
other provide results. before on pipeline move Now programs like of some to brief highlights of financial we to a our few I’d
pathway first Let’s targeting down key without the alternative conversion of the complement the to to pathway. the is or to other pro inhibition pathways. factor shuts the alternative and OMSXXX antibody was and functioning the identify first lectin factor responsible is Omeros for our turn of half MASP-X OMSXXX. MASP-X activator the of the as system’s complement its our D affecting franchise. of classical D, MASP-X
initial MASP-X for XXXX expected nocturnal currently or OMSXXX in in PNH, to lead XXXX. market, process the preparation we hemoglobinuria, that our the on and are for as including early clinical antibody for trials, plan to therapeutics completed the or We our safety hemolysis. paroxysmal which extravascular development, late profile, Compared have to indication. dosing, ability or manufacturing slated holds We advantages, PNH believe order significant and intra scale-up both target prevent
the program MASP-X pursuing MASP-X And inhibitors only inhibitors advancing block specific remaining pathway inhibitors as lectin only molecule by as the here, CX, pathways. well we MASP-X, both MASP-X of we to molecule, complement the The is down are small our for As to potent classical. developing target that the in with key alternative similarly oral inhibitors, small pathway, and pathway. alternative of shut enzymatic are administration,
programs Now our inhibitor Omeros OMSXXX, the compulsive are any X PDEX to controls or phosphodiesterase well disorders. addition use or disorder, midyear. to inhibitor for as our as for of exclusively scheduled of for trials begin and let’s any turn PDEX for treatment compulsive Clinical addiction disorder. movement the any
problem to modulate normal forward a that the the to inhibition restoring acute addiction. with compulsive trials, and common opioid and in our the addiction craving addictions. reward chronic depressing relapse the on For the blocks cue both alcohol all and approved brain in a nicotine, significantly OMSXXX and craving, clinical the highly conserved rodents pathway between eating. as well of to trials. inhibitors stress-induced binge treatment mechanism seeing as and levels disorders, well are and the cocaine, addictions as as initial anti-addiction inhibitors addictions across system, focused both humans, effects dopamine PDEX PDEX parts dopamine appear thought look of become animal appears has relapse specifically, to we of the models in which nicotine system, The addiction associated ability OMSXXX without block demonstrated use PDEX hinders by and and we of to agents. currently block of
clinical on of were Addiction, a of and OMSXXX, data agonist, addiction published cocaine by Behavior. other from Journal were in of from X results trial Our in Phase and study, X disorder Journal PPAR-gamma the program, Biochemistry investigators, a Phase the published Pharmacology, consists nicotine use conducted independent
journal. believes GPCR publication manuscript a addition, heroin a study pipeline submitted data program, which discussion In for our our been peer-reviewed from with with X wrap broad the to cardiovascular Phase also including XX Omeros a immunology, up indications, controls in disease has that We’ll it progress. nervous is metabolic, continued exclusively cancer central inflammatory as GPCRs, and and system disorders. with as ranging well
ability are We and of with growth cells, they promise interleukin alpha, checkpoint promoters, against GPRXXX same alpha. interleukin cytotoxic, blood targeting, factor death PD-LX. the associated to At GPCR targets and ligand the X immense gamma and the GPRXXX believe inverse and and TNF of highly-selective our and agonists of support, CTLA-X, or for or immuno-oncology. for and that XX, amphiregulin programmed advancing decreased to specifically data tumor X, and mononuclear a discovered long results others, small time, T-lymphocytes generate compounds small life-threatening or hold levels treatment molecule GPRXXX, necrosis GPRXXX tumor have proteins, and We among the X, cancer. the of one that our protein the receptor for tumor of treatment cytokines human peripheral breast of Treating our GPCR’s increased killing in interferon levels inverse cancer fundamentally list molecules triple-negative represent serious potential sarcomas; and diseases. antagonist change
or T inverse tumor-protecting Regs. population also regulatory GPRXXX of agonists reduce Our the cells T
for other and no GPRXXX time, Omeros inhibitors, constellation even T-cell exist all receptor GPRXXX has the effects constraining To have administration. GPRXXX and chimeric requiring which checkpoint knowledge, while efficacy a than the functions only we inhibitors. our CAR So suppressive tumor of of antigen treatment. to entity that stimulates no intravenous And immune at cancer Consider of both proteins with as other singly or limitations, cancer-related this combination have by and target tumor system critical therapy blocking affects its drug superior a pathways, same shown functions.
that solid by against importance magnitude and Now anti-cancer compounds, XXX promise of targeting to and the excessively care is orally patient other That’s is an drug effective many drug, shared our targets imagine that controlled of available all tumors. our compounds. GPCR of GPCR
around on financial turn quarter programs We you and be and that GPRXXX continue we future. broad products in call results. our that, update expect about Omeros’ programs, other and a to to over and of summary build targets, these for GPCR hearing Mike, a end I’ll intellectual more will the With the first estate near the
